Valuable Targets

D2 receptor antagonists: What They Are and How to Keep Up with the Latest Advances

9 January 2024
3 min read

The D2 receptor is a type of dopamine receptor found in the human body. It plays a crucial role in various physiological and neurological processes. As a G-protein coupled receptor, the D2 receptor is involved in the regulation of dopamine neurotransmission, which affects mood, motivation, and reward. Dysfunction of the D2 receptor has been implicated in several psychiatric disorders, including schizophrenia and addiction. Additionally, the D2 receptor is a target for antipsychotic medications, which work by blocking its activity to alleviate symptoms associated with psychosis. Understanding the role of the D2 receptor is essential for developing therapeutic interventions for psychiatric and neurological conditions.

The analysis of the target D2 receptor reveals a competitive landscape with multiple companies making progress in the development of drugs. Johnson & Johnson, Mitsubishi Chemical Group Corp., Novartis AG, Sanofi, and Viatris Inc. have shown significant growth and have drugs approved for the target. Schizophrenia, bipolar disorder, and bipolar I disorder are the most common indications for approved drugs. Small molecule drugs are progressing rapidly, with intense competition from biosimilars. The United States, Japan, and China are the leading countries in the development of drugs targeting the D2 receptor, with China showing notable progress. Overall, the target D2 receptor presents opportunities for further research and development in the pharmaceutical industry.

How do they work?

D2 receptor antagonists are a type of medication that block or inhibit the activity of the D2 receptors in the brain. D2 receptors are a subtype of dopamine receptors, which are involved in various neurological processes. By antagonizing or blocking the D2 receptors, these medications can modulate the effects of dopamine in the brain.

From a biomedical perspective, D2 receptor antagonists are commonly used in the treatment of psychiatric conditions such as schizophrenia and bipolar disorder. In these disorders, there is an imbalance of dopamine activity in the brain, and D2 receptor antagonists help to reduce the excessive dopamine signaling. By blocking the D2 receptors, these medications can help alleviate symptoms such as hallucinations, delusions, and mood disturbances.

It is important to note that D2 receptor antagonists may also have side effects due to their broader effects on dopamine signaling. These can include movement disorders, such as parkinsonism, as well as metabolic changes and hormonal imbalances. Therefore, the use of D2 receptor antagonists requires careful monitoring and consideration of the potential risks and benefits for each individual patient.

List of D2 receptor Antagonists

The currently marketed D2 receptor antagonists include:

For more information, please click on the image below.

图形用户界面, 应用程序

描述已自动生成

What are D2 receptor antagonists used for?

D2 receptor antagonists are commonly used in the treatment of psychiatric conditions such as schizophrenia and bipolar disorder.  For more information, please click on the image below to log in and search.

应用程序

低可信度描述已自动生成

How to obtain the latest development progress of D2 receptor antagonists?

In the Synapse database, you can keep abreast of the latest research and development advances of D2 receptor antagonists anywhere and anytime, daily or weekly, through the "Set Alert" function. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

图形用户界面, 应用程序

描述已自动生成

Kyverna's KYV-101 has received FDA clearance for a Phase 2 trial, KYSA-7, for advanced Multiple Sclerosis patients resistant to other treatments
Latest Hotspot
3 min read
Kyverna's KYV-101 has received FDA clearance for a Phase 2 trial, KYSA-7, for advanced Multiple Sclerosis patients resistant to other treatments
9 January 2024
KYV-101, a therapeutic agent by Kyverna, has been granted approval by the American FDA for use in a Phase 2 study, KYSA-7, targeting individuals suffering from advanced, treatment-resistant Multiple Sclerosis.
Read →
How to respect the privacy of subjects in clinical trials?
Knowledge Base
2 min read
How to respect the privacy of subjects in clinical trials?
9 January 2024
To safeguard participant privacy in the clinical trial, only initials—rather than full names—should be used in trial documents, particularly those submitted to the sponsor.
Read →
GPN Vaccines Reports Positive Early-Phase Safety and Immune Response for Gamma-PN Vaccine
Latest Hotspot
3 min read
GPN Vaccines Reports Positive Early-Phase Safety and Immune Response for Gamma-PN Vaccine
9 January 2024
GPN Vaccines Announces Encouraging Safety and Immunogenic Response Results in Initial Phase Trial of its Gamma-PN Vaccine.
Read →
Deciphering 5-HT3 receptor antagonists and Keeping Up with Their Recent Developments
Deciphering 5-HT3 receptor antagonists and Keeping Up with Their Recent Developments
9 January 2024
5-HT3 receptor antagonists are drugs that block serotonin receptors, used in managing nausea and vomiting. With ongoing research, these drugs hold promise for future therapeutic applications.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.